A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer
The efficacy and safety of the use of Surufatinib in combination with Sintilimab.
Gastric Adenocarcinoma
DRUG: Surufatinib+Sintilimab
Objective response rate (ORR), Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST, up to 12 months
Disease control rate (DCR), up to 12 months|Progression-free survival (PFS), up to 12 months|Overall survival (OS), up to 24 months
The efficacy and safety of the use of Surufatinib in combination with Sintilimab.